Reunion Neuroscience Inc. (TSX: REUN)
Health Care · Biotechnology · CA
CA$—
— today · — 1Y
Reunion Neuroscience Inc. (TSX: REUN) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Reunion Neuroscience Inc. across four factors: quality 29/100. Its strongest factor is quality.
REUN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.17
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CA$—
- 52-week low
- CA$—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 16
- Next earnings
- —
About Reunion Neuroscience Inc.
Field Trip Health Ltd. is a company based in Toronto, Canada, that specializes in developing and delivering psychedelic-assisted therapies across North America. The firm manages Field Trip Health Centres, which administer psychedelic treatments, and offers Field Trip Digital applications. Additionally, through its Field Trip Discovery division, it conducts research to create innovative psychedelic molecules. The company provides ketamine-assisted therapy for various conditions, including depression, anxiety, and addiction. Field Trip Health Ltd. was founded in 2008.
- ISIN
- CA76134G1037
- Founded
- 2008
- Listed since
- Oct 6, 2020
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.